Interception of cocaine by enzyme or antibody delivered with viral gene transfer

A novel strategy for preventing relapse in recovering drug users

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.

Original languageEnglish (US)
Pages (from-to)880-891
Number of pages12
JournalCNS and Neurological Disorders - Drug Targets
Volume10
Issue number8
StatePublished - Dec 2011

Fingerprint

Viral Genes
Drug Users
Cocaine
Recurrence
Antibodies
Enzymes
Butyrylcholinesterase
Cocaine-Related Disorders
Reward
Pharmaceutical Preparations
Anti-Idiotypic Antibodies
Vaccines
Brain
Transfer (Psychology)
Proteins

Keywords

  • Adeno-associated viral vector
  • Butyrylcholinesterase
  • Cocaine hydrolase
  • Cocaine vaccine
  • Gene therapy
  • Helper-dependent viral vector
  • Monoclonal antibody

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

@article{ca59b7091d7746e2a58c03e88c9a4e21,
title = "Interception of cocaine by enzyme or antibody delivered with viral gene transfer: A novel strategy for preventing relapse in recovering drug users",
abstract = "Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.",
keywords = "Adeno-associated viral vector, Butyrylcholinesterase, Cocaine hydrolase, Cocaine vaccine, Gene therapy, Helper-dependent viral vector, Monoclonal antibody",
author = "Brimijoin, {William Stephen}",
year = "2011",
month = "12",
language = "English (US)",
volume = "10",
pages = "880--891",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Interception of cocaine by enzyme or antibody delivered with viral gene transfer

T2 - A novel strategy for preventing relapse in recovering drug users

AU - Brimijoin, William Stephen

PY - 2011/12

Y1 - 2011/12

N2 - Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.

AB - Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.

KW - Adeno-associated viral vector

KW - Butyrylcholinesterase

KW - Cocaine hydrolase

KW - Cocaine vaccine

KW - Gene therapy

KW - Helper-dependent viral vector

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=84857696691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857696691&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 880

EP - 891

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 8

ER -